Joining forces in the battle against cancer, myocardial infarction or Alzheimer’s disease

09/10/2007 | 当社について

Together with the German Federal Ministry of Research and Education, five German pharmaceutical and medical device companies are starting the “Technology Initiative Molecular Imaging“

from left: Dr. Hertkorn (Boehringer Ingelheim), Karl-Christian Storz (KARL STORZ GmbH & Co. KG), Bundesforschungsministerin Dr. Annette Schavan, Dr. Kaschke (Carl Zeiss), Prof. Dr. Busch (Bayer-Schering) and Prof. Dr. Reinhardt (Siemens)

Early detection of cancer, Alzheimer’s or cardiovascular diseases, effective therapies and greater efficiency throughout the healthcare system – these are the key goals of the “Technology Initiative - Molecular Imaging” which was set forth today by five leading pharmaceutical and medical device companies as well as the German Federal Ministry of Research and Education (BMBF).

Karl-Christian Storz

Bayer Schering Pharma, Boehringer Ingelheim Pharma, Siemens Medical Solutions, Karl Storz and Carl Zeiss will spend a total of 750 million Euros during the next ten years for the development of new methods in molecular imaging. In the next six years, BMBF will also promote cooperative R&D projects in the amount of 150 million Euros.